LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ligand Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

181.99 -0.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

179.25

Max

185.95

Belangrijke statistieken

By Trading Economics

Inkomsten

112M

117M

Verkoop

115M

K/W

Sectorgemiddelde

81.352

77.671

Winstmarge

101.569

Werknemers

68

EBITDA

87M

149M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.03% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-485M

3.6B

Vorige openingsprijs

182.61

Vorige sluitingsprijs

181.99

Nieuwssentiment

By Acuity

56%

44%

329 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2025, 22:02 UTC

Winsten

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec 2025, 21:46 UTC

Winsten

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec 2025, 23:52 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec 2025, 23:36 UTC

Marktinformatie

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec 2025, 23:20 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec 2025, 23:15 UTC

Winsten

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec 2025, 22:59 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec 2025, 22:45 UTC

Marktinformatie

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec 2025, 22:40 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 22:06 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 22:02 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:00 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec 2025, 21:53 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec 2025, 21:50 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

10 dec 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 21:33 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec 2025, 21:32 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec 2025, 21:25 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec 2025, 21:16 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec 2025, 21:15 UTC

Winsten

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

31.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 243.5 USD  31.03%

Hoogste 275 USD

Laagste 220 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.5 / 109.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

329 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat